Web-based intervention to improve quality of life in late stage bipolar disorder (ORBIT): randomised controlled trial protocol by Fletcher, Kathryn et al.
 DRO  
Deakin Research Online, 
Deakin University’s Research Repository  Deakin University CRICOS Provider Code: 00113B 
 
Web-based intervention to improve quality of life in late stage bipolar disorder 
(ORBIT): randomised controlled trial protocol 
Citation:  
Fletcher, Kathryn, Foley, Fiona, Thomas, Neil, Michalak, Erin, Berk, Lesley, Berk, Michael, Bowe, Steve, 
Cotton, Sue, Engel, Lidia, Johnson, Sheri L., Jones, Steven, Kyrios, Michael, Lapsley, Sara, Mihalopoulos, 
Cathrine, Perich, Tania and Murray, Greg 2018, Web-based intervention to improve quality of life in late 
stage bipolar disorder (ORBIT): randomised controlled trial protocol, BMC psychiatry, vol. 18, article 221, 
pp. 1-13. 
DOI: http://www.dx.doi.org/10.1186/s12888-018-1805-9 
 
 
 
 
© 2018, The Authors 
Reproduced by Deakin University under the terms of the Creative Commons Attribution Licence 
 
 
 
 
 
Downloaded from DRO:  
http://hdl.handle.net/10536/DRO/DU:30111707 
STUDY PROTOCOL Open Access
Web-based intervention to improve quality
of life in late stage bipolar disorder (ORBIT):
randomised controlled trial protocol
Kathryn Fletcher1, Fiona Foley1, Neil Thomas1, Erin Michalak2, Lesley Berk3,4, Michael Berk3,4,5,6,7, Steve Bowe8,
Sue Cotton5,6, Lidia Engel8, Sheri L. Johnson9, Steven Jones10, Michael Kyrios11, Sara Lapsley2,
Cathrine Mihalopoulos8, Tania Perich12,13 and Greg Murray1,14*
Abstract
Background: The primary objective of this randomised controlled trial (RCT) is to establish the effectiveness of a
novel online quality of life (QoL) intervention tailored for people with late stage (≥ 10 episodes) bipolar disorder (BD)
compared with psychoeducation. Relative to early stage individuals, this late stage group may not benefit as much
from existing psychosocial treatments. The intervention is a guided self-help, mindfulness based intervention (MBI)
developed in consultation with consumers, designed specifically for web-based delivery, with email coaching support.
Methods/design: This international RCT will involve a comparison of the effectiveness and cost-effectiveness of
two 5-week adjunctive online self-management interventions: Mindfulness for Bipolar 2.0 and an active control
(Psychoeducation for Bipolar). A total of 300 participants will be recruited primarily via social media channels. Main
inclusion criteria are: a diagnosis of BD (confirmed via a phone-administered structured diagnostic interview), no
current mood episode, history of 10 or more mood episodes, no current psychotic features or active suicidality, under
the care of a medical practitioner. Block randomisation will be used for allocation to the interventions, and participants
will retain access to the program for 6 months. Evaluations will be conducted at pre- and post- treatment, and at 3-
and 6- months follow-up. The primary outcome measure will be the Brief Quality of Life in Bipolar Disorder Scale (Brief
QoL.BD), collected immediately post-intervention at 5 weeks (T1). Secondary measures include BD-related symptoms
(mania, depression, anxiety, stress), time to first relapse, functioning, sleep quality, social rhythm stability and resource
use. Measurements will be collected online and via telephone assessments at baseline (T0), 5 weeks (T1), three months
(T2) and six months (T3). Candidate moderators (diagnosis, anxiety or substance comorbidities, demographics and
current treatments) will be investigated as will putative therapeutic mechanisms including mindfulness, emotion
regulation and self-compassion. A cost-effectiveness analysis will be conducted. Acceptability and any unwanted
events (including adverse treatment reactions) will be documented and explored.
Discussion: This definitive trial will test the effectiveness and cost-effectiveness of a novel QoL focused, mindfulness
based, online guided self-help intervention for late stage BD, and investigate its putative mechanisms of therapeutic
action.
Trial registration: ClinicalTrials.gov: NCT03197974. Registered 23 June 2017.
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Quality of life, Stage, Depression, Mania
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Background
Bipolar disorder (BD) is a serious mental disorder affect-
ing approximately 4% of the adult population [1]. Large
prospective and cross-sectional studies suggest that
about 50% of people diagnosed with BD can be consid-
ered ‘late stage’ (experiencing ≥10 mood episodes) [2, 3].
This ‘late stage’ group carry a disproportionate burden of
functional impairment and chronic depressive symptoms
[3], double the risk of relapse, and significantly impaired
functioning and QoL [3]. Stage of illness impacts prog-
nosis, course outcome and treatment needs. There is
evidence that responsivity to pharmacotherapy varies by
stage of illness, and there is similar evidence for some
psychotherapies [4].
Adjunctive psychological treatment for late stage BD
Current adjunctive psychological treatments for BD em-
phasise relapse-prevention by monitoring triggers and
avoiding stress. However, this may be detrimental to
self-esteem in late stage BD where relapse is often unre-
lated to discernible life events [5]. Indeed, having experi-
enced more than 12 episodes of BD has been found to
predict a negative response to cognitive behaviour ther-
apy (CBT) [6]. In late stage BD, therefore, symptom-fo-
cused treatments may be less beneficial than approaches
that recognise the unavoidability of suffering, emphasise
redefinition of life goals, and prioritise QoL outcomes
[7, 8]. These priorities are consistent with the “third
wave” [9] or contextual cognitive-behavioural therapies
[10], which typically prioritise mindfulness - an aware-
ness of present experience and a non-judgemental stance
towards that experience [11].
Empirical research into mindfulness based interven-
tions (MBIs) for BD has primarily explored face-to-face
delivery, with Mindfulness Based Cognitive Therapy
(MBCT) [12] the primary target of investigation. Studies
report benefits for BD symptoms and associated psycho-
logical variables, in particular anxiety and emotion regu-
lation [13]. Beneficial effects of MBIs in other domains
have been reported including QoL [14], well-being,
stress and rumination [15]. Evidence for effects on
relapse prevention is limited: one study found no bene-
fits for bipolar relapse [16], while another found de-
creased depressive relapse in a bipolar subset of people
with recurrent depression [17]. A recent meta-analysis
on the efficacy of MBIs as an adjunctive treatment for
BD showed significantly beneficial effects on depressive
and anxiety symptoms in within-group analysis [18].
However, this significance was not observed in compari-
son with control groups, limiting conclusions due to the
small number of controlled studies and small sample
sizes. Furthermore, studies examining mindfulness as
part of another treatment modality (e.g., Acceptance and
Commitment Therapy; ACT) were excluded from their
review, as were short-duration (< 3 week) interventions
and self-help interventions delivered online [8]. A fur-
ther limitation of studies to date is their focus on symp-
tom/distress reduction, which is at odds with the main
goals of CCBT approaches [19]. Mechanisms of action of
such approaches are still unclear, as process variables
(e.g., mindfulness, acceptance, self-compassion) have not
been examined in mediational analyses. In summary, fur-
ther clinical trials are needed to determine the efficacy
of MBIs for improving QoL in BD and understanding
their mechanisms of action.
Maximising access to adjunctive psychological treatments
Web-based psychological interventions have great
potential to complement treatment as usual and over-
come barriers to accessing psychological assistance for
BD (e.g., cost, time, trust in professionals) [20]. Such in-
terventions have demonstrated short- and long-term
benefits for a range of mental disorders [21] and are ac-
ceptable to people with BD [22, 23]. There is a lack of
consistent evidence regarding effectiveness of web-based
psychological interventions for BD as most trials to date
have focused on feasibility. Recent findings confirm that
MBIs are effectively delivered via the web [24], including
for mood disorder populations [25]. The benefits of low
intensity web-based interventions are yet to be widely
disseminated to people with BD, highlighting difficulties
in translation into practice.
Development and piloting of the current intervention
Our international team of researchers, clinicians and
consumers developed and piloted a novel, guided
self-help web-based psychological intervention to im-
prove QoL in late stage BD [8]. The low-intensity MBI is
specifically tailored for late stage BD, drawing from Ac-
ceptance and Commitment Therapy (ACT), Mindfulness
Based Cognitive Therapy (MBCT) and Compassion-fo-
cused Therapy (CFT). The intervention was originally
named ORBIT (Online, Recovery-oriented, Bipolar Indi-
vidualised Tool), but to keep participants unaware of the
present trial’s hypothesised superior condition, ORBIT
now refers to the project as a whole. For this report, the
active intervention is titled ‘Mindfulness for Bipolar 2.0’
and the active control condition is titled ‘Psychoeduca-
tion for Bipolar’, but: to minimise expectancy effects, the
names and key features of each arm are not mentioned
in recruitment or consent processes.
Published pilot data suggests the first iteration of
Mindfulness for Bipolar was feasible, safe and potentially
effective in improving QoL [8]. No further published
studies have investigated web-based MBIs specifically
tailored for late stage BD. However, in related severe and
chronic mental illness populations, there is support for
the efficacy of generic MBIs and MBCT [26, 27], as well
Fletcher et al. BMC Psychiatry  (2018) 18:221 Page 2 of 13
as ACT [28, 29]. Evidence suggests that those with
chronic mental illness benefit from mindfulness strategies
to mitigate the distressing effects of symptoms (via mind-
ful acceptance of internal experiences), and improve
self-concept (via promoting an experience of self as obser-
ver, moderating self-evaluations and encouraging commit-
ment to valued goals despite symptoms) [30]. Indeed,
there is evidence that those with a significant BD history
may specifically benefit from a bipolar-tailored version of
MBCT [15, 31, 32].
The present project
Building on pilot study findings, we now describe the
development of and protocol for a definitive RCT of the
second iteration of the MBI (Mindfulness for Bipolar
2.0) for improving QoL in late stage BD.
The overarching aim of the present RCT is to assess
the effectiveness and cost-effectiveness of a novel,
web-based intervention in improving QoL in late stage
BD vs. an active control.
The trial’s primary hypothesis
Relative to an active control (Psychoeducation for Bipolar),
it is predicted that Mindfulness for Bipolar 2.0 will
significantly improve QoL (baseline to endpoint change)
on the Brief QoL.BD [33] immediately post-intervention.
Data will additionally be collected at three and six months
post-baseline, allowing examination of the trajectory of
intervention effects over time.
Secondary hypotheses
It is anticipated that relative to Psychoeducation, the
Mindfulness intervention will improve QoL across the
full 6 months of the trial. A significant time X group
assignment effect is therefore predicted. It is further
anticipated that, relative to Psychoeducation, the Mind-
fulness condition will be associated with improvements
in self-rated anxiety, self-rated depressive syndrome,
observer rated depression, and attrition rates. Possible
group differences will also be explored in a range of sec-
ondary outcomes for which directional predictions are
not made: observer-rated manic symptoms; functional
impairment; functionally oriented measure of QoL; sleep
quality, social rhythm stability, and episode relapse (time
to first). It is also anticipated that the Mindfulness con-
dition will be more cost-effective than Psychoeducation.
Potential moderators and mediators of treatment effects
will also be explored as described below.
Method
This trial is conducted by an international multidiscip-
linary team of researchers and clinicians in Australia,
Canada, USA and the UK. The study was reviewed and
approved by Swinburne University of Technology
Human Research Ethics Committee (2016/289). Trial
objectives and protocol align with all aspects of Good
Clinical Practice [34], the WHO Trial Registration Data
Set (Version 1.2.1) and Standard Protocol Items: Recom-
mendations for Interventional Trials (Additional file 1)
guidelines [35]. The trial has been registered with Clini-
calTrials.gov (NCT03197974). Any changes to this trial
protocol will be described in this trial registry. Findings
will be reported to the scientific community according
to Consolidated Standards of Reporting Trials (CON-
SORT) eHEALTH criteria [36].
Trial design
The trial is a prospective, parallel group, rater-blind,
superiority RCT with a one-to-one allocation ratio
comparing the Mindfulness for Bipolar 2.0 intervention
with a structurally equivalent, validated and therapeutic-
ally credible active control condition (Psychoeducation
for Bipolar). The primary endpoint is immediately post-
treatment (upon completion of the 5-week intervention).
Follow-up time points are at 3-months and 6-months.
Both interventions are guided self-help, and not
intended to replace treatment as usual. The study setting
is online, and participation in both arms occurs through
a secure server.
Randomisation
Participants will be sequentially allocated to intervention
arms using a one-to-one ratio by predetermined per-
muted block randomisation with a block size of 10. The
permutation sequence within blocks will be randomly
generated by SAS Version 9.4, overseen by an off-site
statistician, and coded into the website so randomisation
is automated and free of potential allocation bias. Partic-
ipants are unaware of the primary hypothesis of the
study, and have no prior knowledge of the two interven-
tion types, but are unavoidably aware of the intervention
to which they have been randomised. To reduce expect-
ancy effects for superiority of the intervention over the
control condition, the trial is framed as a comparison
between two interventions designed to improve QoL.
Assessors will remain unaware of treatment condition,
and assessors who become aware of the treatment con-
dition will, if possible, be replaced. Success in keeping
assessors unaware of the treatment condition will be
quantified by asking interviewers to guess allocation
upon completion of the RCT, and assessing whether they
can do so at greater than chance levels. Statistical
analyses will be conducted blind to treatment allocation
by an off-site statistician.
Recruitment and assessment
The study will be administered and conducted through a
single-site, with recruitment primarily via open social
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media sites (e.g., International Bipolar Foundation Face-
book site). Recruitment will also be facilitated in four
English-speaking countries via advertisements dissemi-
nated online through public and mental health sites and
social media, listservs and traditional advertisements
(offline) posted in clinical services.
As summarised in the flow diagram (see Fig. 1), indi-
viduals interested in participating will be invited to visit
the study website (https://www.orbitonline.org/) where
they can sign up, view and provide their consent to the
participant information and consent form, provide their
contact details (including details of their medical health
professional), and respond to initial screening questions
regarding eligibility (i.e., received a diagnosis of BD from
a mental health professional, experienced 10 or more
mood episodes).
An assessor from the research team will then contact
potential participants via telephone to conduct the first
component of the baseline assessment (T0) to confirm
eligibility criteria and assess comorbidities. Potential
participants deemed eligible except for current episode
status/psychotic symptoms/active suicidality (see exclu-
sion criteria below) will be offered a later assessment
(one month following initial phone call) to determine
eligibility at that time. Eligible participants will complete
the second component of the baseline assessment
(online questionnaires) (T0), followed by randomisation.
An online coach will be assigned to the participant
(contact initiated via a ‘welcome’ message). Participants
will be asked to complete post-intervention (5-weeks,
T1), 3-month (T2) and 6-month (T3) post-baseline
assessments, involving a telephone interview and online
questionnaires (see Table 1 for schedule of assessments).
Participation in each assessment (phone and online
components) will be compensated with USD$25 gift
vouchers.
Assessors (masters-level in psychology) will be trained
on study measures. Inter-rater reliability will be
Fig. 1 Participant flow diagram
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established for key observer-rated outcome measures
(i.e. Montgomery-Asberg Depression Rating Scale,
MADRS; Young Mania Rating Scale, YMRS), telephone
assessment interviews will be recorded (except for
participants who decline), and inter-rater checks will be
conducted every three months. If rater drift is identified,
assessors will be retrained.
Strategies to maximise data quality
Online questions will be made mandatory where possible to
reduce missing data. Comprehensive data cleaning (range
and other distributional checks, comparison with published
norms where relevant) will be conducted prior to analyses.
Inclusion criteria
To ensure ready translation, minimally restrictive inclu-
sion/exclusion criteria have been set. Inclusion criteria
are as follows:
(1) Aged 18–65 years
(2) Received a diagnosis of BD from a mental health
professional (GP or Psychiatrist)
(3) Confirmation of DSM-IV diagnosis of BD as assessed
by telephone interview with the M.I.N.I. International
Neuropsychiatric Interview (MINI) [37]
(4) experienced 10 or more episodes of mania, hypomania
or depression (assessed within the context of the
MINI and assessor prompts, e.g., life events)
(5) under the care of a medical practitioner (at least
one contact within the past 12 months) and able
to provide contact details of local emergency
service
(6) sufficient understanding of written and spoken
English to provide informed consent and engage
with the intervention
(7) ready daily access to the internet and adequate
internet literacy
Table 1 Schedule of assessments
Measure Modality T0 baseline T1 (5 weeks
post-baseline)
T2 (3 months
post-baseline)
T3 (6 months
post-baseline)
MINI Neuropsychiatric Interview (including
Columbia Suicide Severity Rating Scale, C-SSRS)
Telephone X X X X
Brief Quality of Life in Bipolar Disorder (QoL.BD) Online X X X X
Montgomery-Asberg Depression Rating Scale
(MADRS)
Telephone X X X X
Young Mania Rating Scale (YMRS) Telephone X X X X
Quick Inventory of Depressive Symptoms-Self
Report (QIDS-SR)
Online X X X X
DASS-21 (anxiety and stress sub-scales) Online X X X X
Functioning Assessment Short Test (FAST) Telephone X X X X
Pittsburgh Sleep Quality Index (PSQI) Online X X X X
Sleep, Circadian Rhythms and Mood
questionnaire (SCRAM)
Online X X X X
Resource Use Questionnaire (RUQ) Online X X X
Assessment of Quality of Life-Eight Dimension
(AQoL-8D)
Online X X X X
Five Facet Mindfulness Questionnaire (FFMQ) Online X X X X
Self-Compassion Scale (SCS) Online X X X X
Difficulties in Emotion Regulation Scale-16 item
(DERS-16)
Online X X X X
Ruminative Response Scale-10 item (RRS-10) Online X X X X
Responses to Positive Affect scale (RPA) Online X X X X
Nonattachment to Self Scale Online X X X X
Depressive Experience Questionnaire-Self
Criticism Six-item Scale (DEQ-SC-6)
Online X X X X
Short Form of the Revised Almost Perfect
Scale (SAPS)
Online X X X X
Medication adherence Online X X X X
User feedback and engagement Online and telephone X X X
Reasons for withdrawal Telephone X X X
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Exclusion criteria
Exclusion criteria are as follows:
(1) experiencing a current episode of depression,
hypomania or mania (assessed by MINI)
(2) currently psychotic (assessed by MINI)
(3) active suicidal ideation (assessed by Columbia
Suicide Severity Rating Scale, C-SSRS) [38]
Risk management
Risk management procedures have been developed
through our experience with other online interventions
and websites for BD [22, 39–43] and through consult-
ation with the CREST.BD Community Advisory Group.
Procedures pay particular attention to suicide risk, dis-
tinguish between solicited and spontaneously reported
events, and are reviewed weekly during the trial by the
study’s executive committee. To minimise impact of any
adverse events, being under the care of a medical practi-
tioner is an inclusion criterion, and participants consent
to this professional potentially being contacted by the re-
searchers as part of a ‘red flag decision tree’ (detailed
below). The informed consent statement explains that
the medical practitioner or local emergency department
remains the participant’s first point of contact. Both the
pre-registration page and informed consent statement
highlight participants’ central role in their own safety and
wellbeing, emphasising that the website does not act as an
emergency service, and that the website is not monitored
in real time. Links to emergency resources will be pro-
vided on the website (e.g., unsuicide.wikispaces.com).
Participants will be withdrawn from the trial if their par-
ticipation compromises clinical care as determined by the
study’s executive committee. On a case-by-case basis, this
might include hospital admission, acute hypomania or
mania, psychotic symptoms or active suicidal intent.
Adverse events will be monitored via questions at
post-test and both follow-up time points, and any ad-
verse events incidentally reported through participant
contact with coaches, forum posts, or assessments will
also be recorded. Severity of any adverse events, and
causal relationship to the trial will be assessed through
participant self-report and logged. Adverse events will
be reviewed at monthly executive meetings and
6-monthly meetings of the independent trial committee
(who will also explore patterns of adverse events by con-
dition). Serious adverse events suspected or known to be
related to participation in the trial will be reported to
Swinburne University of Technology Human Research
Ethics Committee.
Clinical risks emerging will be addressed through a de-
tailed ‘red flag decision tree’ which captures the various
points at which the researchers could become aware of
risk information (particularly suicidality), namely, baseline
and follow-up (post-intervention, 3-month, 6-month)
assessment interviews, posted comments on the website
(e.g., forum content) and communications with the online
coach (see below). Red flag events are those where there is
immediate risk of harm (e.g., scoring high on suicide
items, forum posts or coach emails suggesting active
suicidality), as contrasted with other concerns highly
prevalent in this population (e.g., comments about waxing
and waning symptoms, connectedness or distress). Only
in the former case have participants consented for re-
searchers to break confidentiality and communicate with
their clinician or emergency services, and these events are
considered red flags for action of some kind. The decision
tree distinguishes between red flag information suggesting
immediate risk of harm for which real-time intervention
is feasible/recommended (e.g., when active suicidality is
identified during a phone assessment), and when it is not
(e.g., when the research team becomes aware of active
suicidality mentioned in a forum post from 48 h previous).
All trial staff will be comprehensively trained on protocol
procedures.
Intervention content
To minimise attrition and non-adherence the interven-
tion is brief, with a 5-week structured participation time,
with each new module released sequentially. Participants
will complete modules at their own pace: content within
modules is organised into ‘chunks’ allowing exploration
in briefer or longer individual sessions, depending on
personal preferences. Suggested guidelines on using the
program to maximise benefit will be provided, including
spending a minimum of 1–2 h each week on content
and ongoing skills-practice (with daily practice recom-
mended for mindfulness skills and mood monitoring).
Both interventions comprise four modules, with new
module content delivered sequentially each week over
four weeks. The fifth week is positioned as an opportun-
ity to consolidate skill development. Participants can
return to previous modules across the program at any
time. To support ongoing generalisation of skills, partici-
pants retain access to the program for the 6-month
follow-up period.
To maximise engagement, the interventions follow
best practice in persuasive system design. Features
known to impact engagement are included: (1) dialogue
support (praise from coach and forum moderator, email
reminders), (2) social support (social facilitation through
discussion threads in moderated forums) and (3)
primary task support (best practice principles for modu-
larisation of content, personalisation/monitoring of pro-
gress, prompted self-monitoring, and rehearsal) [44].
Website presenters include experienced clinical aca-
demics and consumers with lived experience of BD.
Topics within modules are organised primarily around
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videos (2–3 min in length), followed by text, reflective ex-
ercises, audio exercises and additional information PDFs.
Participants can comment publically on videos (via com-
ments feed) and complete exercises which are private but
can be shared with others users of the website.
Coaching support improves adherence to web inter-
ventions [40]. Both interventions therefore include
personal coaching support through asynchronous email
contact with a trained online coach. Participants can
send as many messages as they like to their coach, and
will receive one response per week. Completed activities
can be shared with the coach to facilitate skill develop-
ment. A moderated forum is included to develop a sense
of online community. The forum is moderated by
trained consumers with lived experience of BD, who will
also seed discussion threads with encouraging tips.
Mindfulness for bipolar 2.0
This is a bespoke web-based intervention tightly targeted
at QoL outcomes in late stage BD. Intervention content
is framed around the development of five overlapping
skills: Mindfulness (self-awareness, mindfulness as a tool
for emotion regulation), Values and Committed Action
(identifying personal values as a guide to action), Accept-
ance (of negative experiences, contrasted with struggling),
Defusion (creating distance from unproductive thoughts,
emotions and sensations), and Self-compassion (cultivat-
ing self-compassion in the context of ongoing symptoms
and previous disappointments).
Content draws from best-practice psychological inter-
ventions of potential utility in BD, specifically ACT,
MBCT and CFT [45]. To support generalisation to real
world settings and maintenance upon completion of the
5-week active phase, classical principles of behaviour
change (as commonly used, for example, in Cognitive Be-
havioural Therapy) are applied. Website aesthetics, struc-
ture and navigation are informed by our previous
experience, particularly development of a web-based inter-
vention for people with serious mental disorder [46].
Intervention content is well suited to web delivery,
using multi-media tools (video, audio, downloadable in-
formation sheets, etc.) to introduce skills that partici-
pants can practice experientially with well-planned
exercises. Real-world application of skills is emphasised
throughout, and facilitated through online and down-
loadable goal-setting and monitoring tools.
Psychoeducation for bipolar
Psychoeducation is a meaningful comparator given that
it is beneficial as an adjunctive treatment for BD and is
readily translated into web format [47]. The active
control condition here, Psychoeducation for Bipolar, is a
5-week, web-based guided self-help intervention in-
formed by the approach of Colom and Vieta [48].
Material is organised into four modules (Bipolar and
You, Treatments, Knowing the Signs, and Staying Well),
with a focus on factual information about BD including
available medications and treatments, skill development
(mood monitoring, recognising triggers and early warn-
ing signs) and strategies to stay well (lifestyle factors,
coping behaviours, crisis planning).
Outcome measurements
The schedule of assessments is provided in Table 1.
Assessments are performed as close as practicable to
specified time points. All clinician-rated assessments are
conducted by telephone by expertly trained assessors,
unaware of treatment allocation. All self-report assess-
ments are completed online via a secure, encrypted
online survey platform (Qualtrics). Participants are con-
tacted via email to arrange a time for phone assessments
and to prompt completion of online assessments. If an
email response is not received within two days, an SMS
reminder is sent to the participant. Assessors will moni-
tor the completion of questionnaires on a regular basis
and make telephone calls to facilitate completion where
such support may be required. The MINI is conducted
via telephone at baseline to confirm eligibility, establish
comorbid diagnoses and record demographic variables.
Primary outcome measure
The primary outcome, QoL, will be measured at T1
using the total score of the Brief QoL.BD [33]. This
measure was developed specifically for repeated
measures use, assessing 12 factor-analytically derived
domains (Physical, Sleep, Mood, Cognition, Leisure,
Social, Spirituality, Finance, Household, Self-esteem,
Independence, and Identity) from the parent instrument
(the 56-item Qol.BD). The parent instrument has dem-
onstrated strong effect size associations with objective
measures of functioning [49], generic QoL measures
[33], and BD-linked cognitive processes [50]. In the
validation sample (N = 224 patients), Cronbach’s α for
the 12 items of the Brief QoL.BD was 0.87, and standard
deviation of total scores was 8.76, giving a reliable
change on the Brief QoL.BD of 3.16 points [33]. Sensi-
tivity analysis found the 12-item Brief QoL.BD had
superior sensitivity to change in clinician-rated symp-
toms than commonly used generic QoL measures. Brief
QoL.BD scores have been shown to be sensitive to inter-
vention effects in two published RCTs [22, 51], and the
measure has been validated for online use.
Secondary outcome measures
The following measures will be used to assess secondary
outcomes. Each measure will be administered at T0, T1,
T2 and T3 (see Table 1).
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1. Montgomery-Asberg Depression Rating Scale
(MADRS) [52]. A gold standard, psychometrically
sound interviewer-rated scale to assess depression
symptoms.
2. Young Mania Rating Scale (YMRS) [53]. A gold
standard, psychometrically sound interviewer-rated
scale to assess manic symptoms.
3. Quick Inventory of Depressive Symptomatology-
Self-Report (QIDS-SR) [54]. A self-report measure
of depression symptoms with high internal
consistency (α = 0.87), that correlates highly with
established clinician-rated scales including the
Hamilton Rating Scale of Depression (r = 0.86) [54].
4. Depression Anxiety Stress Scale (DASS-21) [55]. A
valid and reliable self-report measure of depression,
anxiety and stress (total scores and the latter two
sub-scales will be used).
5. Functioning Assessment Short Test (FAST) [56].
An interviewer-rated measure evaluating functional
impairment across six different domains (autonomy,
occupational functioning, cognitive functioning,
financial issues, interpersonal relationships, leisure
time), validated in patients with BD. The measure
has excellent test-retest reliability and internal
consistency (α = 0.95) [57, 58].
6. Pittsburgh Sleep Quality Index (PSQI) [59]. One of
the most widely used self-report measures of sleep
quality. The components and items have
demonstrated strong internal consistency; global
and component scores have been shown to be
stable over time [59].
7. Sleep, Circadian Rhythms and Mood questionnaire
(SCRAM) [60]. A self-report measure to assess
overlap between sleep, circadian rhythms and
mood. Preliminary psychometric analyses indicate
adequate test-retest reliability and good internal
consistency (α = 0.80).
8. Relapse. The MINI [37] will be conducted at each
assessment to determine illness episodes. The Time
to relapse measure (TIME) [61] assesses relapse or
time to intervention, with intervention defined as
initiation, discontinuation, or dose adjustment of
a treatment, initiation of psychotherapy or
electroconvulsive therapy, visit to an emergency
provider or hospitalisation in response to new
mood symptoms.
Other outcome measures and mechanism variables
The following measures will be administered at T0, T1,
T2 and T3 (see Table 1), with the exception of the
Resource Use Questionnaire (administered at T0, T2
and T3 in order to standardise timeframe assessment for
economic analyses).
1. Resource Use Questionnaire (RUQ, unpublished).
Although differences in service use are not formally
hypothesised as an outcome of the intervention, the
self-reported RUQ assesses for any differences in
mental health service utilisation between groups
before, during, and following the intervention. To
derive costing for the economic analysis, this study
will use a purpose designed RUQ, which is largely
based on previous RUQs used by the study team in
other mental health economic evaluations. The
RUQ was modified for the international context
of the study, assessing direct health care costs
(including out-of-pocket costs) and productivity
costs. RUQ information will be supplemented by
Australian Government Medicare data and Pharma-
ceutical Benefits Schedule for Australian participants.
2. Assessment of Quality of Life-Eight Dimension
(AQoL-8D) [62]. A self-report measure to assess
health-related QoL for use in economic evaluations
that has been comprehensively validated and
demonstrated high test-retest reliability [63] .
3. Five Facet Mindfulness Questionnaire (FFMQ) [64].
A self-report measure of the dispositional tendency
to be mindful in daily life. The 39-item measure has
satisfactory internal consistency and demonstrates
good sensitivity to change [65–67].
4. Self-Compassion Scale (SCS) [68]. A self-report
measure assessing the degree of self-compassionate
responding towards oneself during hard times. A
recent examination of the 26-item measure
indicated it is a psychometrically valid and theoret-
ically coherent measure of self-compassion [69] .
Excellent internal consistency (α = 0.89) for the total
score was demonstrated in a bipolar sample [70].
5. Difficulties in Emotion Regulation Scale-16 item
(DERS-16) [71]. A self-report measure to assess
overall emotion regulation difficulties. The measure
has excellent internal consistency (α = 0.92) and
good test-retest reliability [71].
6. Ruminative Response Scale (RRS-10) [72]. A
self-report measure of tendency to ruminate,
with adequate internal consistency and test-retest
reliability.
7. Responses to Positive Affect Scale (RPA) [73]. A
self-report measure to assess rumination and damp-
ening regulation strategies. Tests of convergent val-
idity support associations between sub-scales and
mood measures, and acceptable internal consistency
was established in a bipolar sample [74].
8. Nonattachment to Self Scale (Whitehead et al.:
Letting go of self: nonattachment-to-self and its re-
lationship to depression, anxiety and stress. Submit-
ted). A self-report measure to assess the degree of
dispassion/non-attachment to self-concept. The
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initial validation study (unpublished) of the scale
demonstrated
good internal consistency (α = 0.86), and robust cor-
relations with other constructs in expected
directions (e.g., mindfulness for convergent validity;
depersonalization for discriminant validity).
9. Depressive Experience Questionnaire Self-Criticism
Six-Item Scale (DEQ-SC6) [75]. A self-report
measure to assess trait self-criticism, with adequate
internal consistency (up to α = 0.84) and expected
associations with pertinent constructs (e.g.,
emotional distress).
10. Short revised Almost Perfect Scale (SAPS) [76]. A
self-report measure to assess perfectionism, with
adequate internal consistency (up to α = 0.87).
Convergent and discriminant validity was demon-
strated with other indicators of perfectionism; as
was criterion-validity in terms of associations with
other constructs (e.g., conscientiousness, neuroti-
cism, emotion regulation and depression).
11. Adherence to Medication. A self-report question
with five response options regarding degree of
adherence to medication over the past month.
12. User feedback and engagement. Participants are
invited to provide feedback about the program
immediately post-treatment. Usage of the site, and
frequency/duration of application of skills/know-
ledge is assessed via self-report at the three major
assessment time points (see Table 1). Upon comple-
tion of the post-intervention assessments, a subset
of participants from each arm will be selected to
participate in a recorded qualitative phone interview
(with an investigator who is independent of study
assessments) regarding their engagement with, and
experience of the intervention.
13. Program usage. This is tracked automatically by
the website, and data will be used to develop an
algorithm operationalising use/adoption, which
combines activity completion and active
engagements with the intervention [77].
14. Reasons for discontinuation from study. Participants
requesting to discontinue their participation will
be asked (via a brief phone call from the trial
coordinator) for main reasons for discontinuation,
with any adverse events documented.
Statistical analysis plan
Sample size was determined by power analysis using
G*Power 3. Analyses were conducted on the primary
endpoint (Brief QoL.BD score) at T1 relative to baseline.
Based on our pilot study (intent-to-treat d = 0.52), and
Brief QoL.BD change in comparable RCTs [22, 51], a
between-group effect size of d = 0.4 was conservatively es-
timated. This small-to-moderate effect size is comparable
to effect sizes found for adjunctive CBT on a range of out-
comes in BD [78], and therefore can be considered a clin-
ically important difference given the new intervention is
low intensity, low cost, and high access. A sample size of
200 (100 in Mindfulness for Bipolar 2.0 and 100 in
Psychoeducation for Bipolar) would provide at least 80%
power (1-β) to detect an effect of this size at α = 0.05
(two-tailed). Attrition at immediate follow-up was conser-
vatively estimated at 33% based on attrition rates in the
pilot study and our earlier RCT of a web-based interven-
tion for BD [39], so N = 300 randomised participants are
required to generate the required sample size of 200 for
the primary analysis.
Statistical analysis of primary outcome
Changes from baseline to immediate post-test in QoL.BD
scores are hypothesised to be significantly greater in the
Mindfulness versus Psychoeducation group. Statistical
analyses will be conducted in accordance with the Inter-
national Conference on Harmonization E9 statistical prin-
ciples. All treatment-related effects will be estimated using
intention-to-treat: all randomised participants will be ana-
lysed. We will attempt to follow and assess all participants
regardless of level of usage of the site during the interven-
tion period (with the exception of those explicitly discon-
tinuing, or being withdrawn on ethical grounds).
Sensitivity analysis of primary outcome
In order to corroborate the robustness of the primary
outcome, the following sensitivity analyses will be
performed:
(a) Per protocol analysis: estimation of the treatment
effects in those participants who actually receive the
intervention. For analytic purposes, these analyses
will be restricted to participants who complied with
the treatment protocol, defined as (i) completed all
assessments required for the analysis, and (ii)
received a minimal dose of the intervention
(b) Intention to treat multivariate regression analysis
with imputation, and adjusting for the baseline
variables used to impute missing data. For subjects
with missing data at either time- point, scores will
be imputed using multiple imputation with 20
resamples, and imputing baseline variables age,
gender, diagnosis, number of episodes, depression
symptoms, country of residence and any relevant
data collected post-randomisation (specific analytic
method will depend on patterns of missingness in
the data). Missing data will be imputed using
predictive mean matching, using the 10 nearest
neighbours.
(c) As in (b) above, but using only observed data.
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Time trend analysis of QoL
To investigate the secondary outcome of expected
superiority of Mindfulness for QoL outcomes across the
full 6 months of the trial, an intention to treat mixed
model analysis using T0, T1, T2 and T3 QoL.BD scores
will be undertaken.
Secondary outcome measures
Treatment-related change in secondary outcomes analyses
will be identical to those described above for the primary
outcome. It is anticipated that relative to Psychoeducation,
the Mindfulness condition will be associated with im-
provement in three outcomes: (a) self-rated state anxiety
(DASS-Stress, DASS-Anxiety), (b) self-rated depression
(QIDS-SR) and (c) clinician-rated depression (MADRS). It
is also anticipated that relative to Psychoeducation, the
Mindfulness condition will be associated with decreased
dropout attrition.
Analysis of treatment-related change in remaining sec-
ondary outcomes will be exploratory. Time to first relapse
will be analysed using multivariate survival analysis [79].
Mechanism analyses
A series of parallel multiple mediation analyses will be
conducted to examine the effects of putative treatment
mechanisms on QoL [80, 81]. It is anticipated that thera-
peutic effects of the Mindfulness intervention on QoL
will be mediated by improvements in mindfulness,
self-compassion and emotion regulation. Exploratory
analyses will be undertaken with regards to nonattach-
ment to self, self-criticism and perfectionism. It is antici-
pated that the therapeutic effects of the Psychoeducation
intervention on symptoms of mania and depression, and
relapses into mania and depression will be mediated by
(i) self-reported adherence to medication, and (ii)
biological rhythm stabilisation (SCRAM).
Moderators of treatment effects
Although no baseline moderators are predicted to ex-
plain significant variance in outcome (and consequently
stratification is not used in allocation), a signal across
standard baseline variables (age, gender, diagnosis, num-
ber of episodes, depression symptoms, and country of
residence), and the putative mediating variables (above)
will be explored. Potential confounds of medication use/
changes and use of structured psychological interven-
tions during follow-up will be tracked.
Economic analyses
A cost-effectiveness and a cost-utility analysis will be car-
ried out alongside the ORBIT trial from both a societal
perspective and a health sector perspective. Evaluation will
first measure and value any change to the use of health
care resources over the period of the study between the
two interventions, and then compare any additional costs
to the outcomes achieved. Standardised economic evalu-
ation techniques will be used including incremental
analysis of mean differences and bootstrapping to deter-
mine confidence intervals. Quality-of-adjusted life years
(QALYs) will be derived from the AQoL-8D that will form
a cost-utility analysis and the Qol.BD will be used for the
cost-effectiveness analysis. Costs considered in this eco-
nomic analysis include: (i) intervention costs, (ii) direct
health care costs (including out-of-pocket costs), and (iii)
productivity costs (absenteeism, presenteeism and unpaid
work) [82, 83]. As it is anticipated that most participants
will be recruited in Australia, a one-country costing ap-
proach will be applied using cost estimates from Australia
[84]. Sensitivity analyses will be used to determine the im-
pact of important study parameters (such as unit cost
price variation). Australian participants will be asked for
consent to provide access to routine data on use of health
care services through Medicare (Health Insurance Com-
mission) and the Pharmaceutical Benefits Schedule.
Depending on the results, modelling may also be used to
extrapolate beyond the trial time horizon.
Discussion
This study constitutes a definitive investigation of a
novel intervention aimed specifically at improving QoL
in late stage BD. Consistent with Mental Health
Research Network good practice guidelines and the prin-
ciples of consumer engagement in research and treat-
ment development [85, 86], the intervention has been
developed in partnership with individuals with lived
experience of BD.
The intervention exemplifies a significant shift in psy-
chosocial approaches to BD. It is one of the few to investi-
gate stage of illness-based approaches to psychotherapy,
MBIs for BD, and the first to adopt a web-based platform
for offering MBIs to this population. The intervention is
innovative in targeting the consumer-focused priority of
improving QoL; offering tailored content for late stage BD
including use of lived experience material to complement
third-wave psychological approaches; and adopting fea-
tures of persuasive system design to maximise adherence
and engagement. Examination of mechanisms of change
associated with this MBI will elucidate putative treatment
targets, informing both the use of this intervention as well
as refining future interventions for BD.
The trial will contribute a rigorously evaluated interven-
tion to the growing literature on low-intensity web-based
self-management programs for BD.
Several limitations are noteworthy. First, while the
intervention is accessible via multiple platforms (com-
puter, tablet, smartphone), it does not currently support
technical integration with mobile health (mHealth) or
popular wearable technologies (e.g., actigraphy devices),
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which have strong potential for objective monitoring in
BD [87, 88]. These restrictions arise from both resource
limitations and the study’s scientific aim of tracking en-
gagement through the website itself. Future versions of
the intervention will seek to integrate such technologies.
Second, the intervention has been specifically designed
for late stage BD. The concept of ‘late stage BD’ remains
poorly characterised, and many questions remain about
illness progression and staging in BD [89]. Here, we em-
ploy the face-valid operationalisation of number of epi-
sodes (assessed by prompted self-report), while
recognising that more theoretical and empirical work is
required into the concept itself. Should study findings
support intervention effectiveness, future RCTs will be
required to determine whether findings generalise to
early and mid-stage BD.
There is room for innovation in the BD psychotherapy
space. Outcomes of this RCT of a low intensity web-based
MBI QoL intervention tailored for late stage BD will be of
great interest to researchers and end-users in light of its
multiple innovations. It will contribute to tailoring therap-
ies to individual needs and profiles, in particular stage of
illness. We hope that positive findings of the RCT will
support immediate scaling up of the intervention as a new
tool for improving outcomes for people with the latter
stage BD.
Trial status
Recruitment is ongoing. It is anticipated that the trial
will be completed (T3) by September 2019.
Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents. (DOC 136 kb)
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